In this week’s video, Dr. Brian G.M. Durie discusses daratumumab’s presence and results in the frontline setting.

BOTTOM LINE: 
​Daratumumab has been successful in the frontline setting for myeloma patients. It will prove to be a new standard of care in many combinations to come.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.